Serum HER-2/neu in the management of breast cancer patients

Clinical Biochemistry

Volumn 36, Issue 4, 2003, Pages 233-240

  Lüftner, Diana ^a   Lüke, Claudia ^a   Possinger, Kurt ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Breast cancer; Chemotherapy; Herceptin; Hormonal therapy; Monitoring; Monoclonal antibody; neu; Prediction; Prognosis; Screening; Serum HER 2

Indexed keywords

ANTIGEN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; METALLOPROTEINASE; MONOCLONAL ANTIBODY; PROTEIN; TRASTUZUMAB; TUMOR MARKER;

BLOOD ANALYSIS; BREAST CANCER; BREAST METASTASIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; ENZYME IMMUNOASSAY; EXTRACELLULAR SPACE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; SENSITIVITY ANALYSIS; SYSTEMIC CIRCULATION; SYSTEMIC THERAPY; TISSUE REACTION;

EID: 0038796897     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(03)00026-2     Document Type: Review

References (38)

1. Padhy L.C., Shih C., Cowing D., Finkelstein R., Weinberg R.A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell. 28:(4):1982;865-871.
2. Bargmann C.I., Hung M.C., Weinberg R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 319:(6050):1986;226-230.
3. Coussens L., Yang-Feng T.L., Liao Y.C., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:(4730):1985;1132-1139.
4. Brandt-Rauf P.W., Pincus M.R., Carney W.P. The c-erbB-2 protein in oncogenesis molecular structure to molecular epidemiology . Crit Rev Oncog. 5:(2-3):1994;313-329.
5. Brandt-Rauf P.W., Monaco R., Pincus M.R. Conformation of the transmembrane domain of the epidermal growth factor receptor. J Protein Chem. 13:(2):1994;227-231.
6. Gullick W.J., Bottomley A.C., Lofts F.J., et al. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein. EMBO J. 11:(1):1992;43-48.
7. Guerin M., Gabillot M., Mathieu M.C., et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer prognostic significance . Int J Cancer. 43:(2):1989;201-208.
8. Codony-Servat J., Albanell J., Lopez-Talavera J.C., Arribas J., Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59:(6):1999;1196-1201.
9. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:(4785):1987;177-182.
10. Pegram M.D., Lipton A., Hayes D.F., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:(8):1998;2659-2671.
11. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-her2 receptor monoclonal antibody, inhibits basal and activated her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:(12):2001;4744-4749.
12. Baselga J., Seidman A.D., Rosen P.P., Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer therapeutic implications . Oncology (Huntingt). 11:(3 Suppl 2):1997;43-48.
13. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:(13):1998;2825-2831.
14. Lebeau A., Deimling D., Kaltz C., et al. Her-2/neu analysis in archival tissue samples of human breast cancer comparison of immunohistochemistry and fluorescence in situ hybridization . J Clin Oncol. 19:(2):2001;354-363.
15. Pauletti G., Dandekar S., Rong H., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer a direct comparison of fluorescence in situ hybridization and immunohistochemistry . J Clin Oncol. 18:(21):2000;3651-3664.
16. McKenzie S.J., Marks P.J., Lam T., et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene. 4:(5):1989;543-548.
17. Cook G.B., Neaman I.E., Goldblatt J.L., et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 21:(2B):2001;1465-1470.
18. Payne R.C., Allard J.W., Anderson-Mauser L., Humphreys J.D., Tenney D.Y., Morris D.L. Automated assay for HER-2/neu in serum. Clin Chem. 46:(2):2000;175-182.
19. Meden H., Mielke S., Marx D., Wuttke W., Kuhn W. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res. 17:(4B):1997;3075-3077.
20. Mielke S., Meden H., Raab T., Wuttke W., Kuhn W. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum. Anticancer Res. 17:(4B):1997;3125-3127.
21. Mehta R.R., McDermott J.H., Hieken T.J., et al. Plasma c-erbB-2 levels in breast cancer patients prognostic significance in predicting response to chemotherapy . J Clin Oncol. 16:(7):1998;2409-2416.
22. Saghatchian M., Guepratte S., Floiras J.L., Paternostre B., Pichon M.F. Correlation of serum erbB-2 concentration with initial clinoco-biological presentation and patients' outcome in primary breast cancer. Proc ASCO. 20:2001;62b.
23. Hayes D.F., Yamauchi H., Broadwater G., et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer Cancer and Leukemia Group B Study 8662 . Clin Cancer Res. 7:(9):2001;2703-2711.
24. Sugano K., Ushiama M., Fukutomi T., Tsuda H., Kitoh T., Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer. 89:(4):2000;329-336.
25. Imoto S., Kitoh T., Hasebe T. Serum c-erB-2 levels in monitoring of operable breast cancer patients. Jpn J Clin Oncol. 29:(7):1999;336-339.
26. Isola J.J., Holli K., Oksa H., Teramoto Y., Kallioniemi O.P. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer. 73:(3):1994;652-658.
27. Molina R., Jo J., Filella X., et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 19:(4A):1999;2551-2555.
28. Molina R., Jo J., Zanon G., et al. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients comparison with carcinoembryonic antigen and CA 15.3 . Br J Cancer. 74:(7):1996;1126-1131.
29. Colomer R., Montero S., Lluch A., et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 6:(6):2000;2356-2362.
30. Harris L.N., Liotcheva V., Broadwater G., et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 19:(6):2001;1698-1706.
31. Lipton A., Ali S.M., Leitzel K., et al. Elevated serum her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 20:(6):2002;1467-1472.
32. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer evidence from a phase III randomized trial . J Clin Oncol. 19:(18):2001;3808-3816.
33. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 20:(7):2002;1800-1808.
34. Lüftner D., Fritz J., Fenner M., et al. Monitoring clinical response to Herceptin-based therapy by serum HER-2/neu measurements in metastatic breast cancer. Clin Chem Lab Med. 39:2001;178.
35. Kostler W.J., Schwab B., Singer C., et al. Predictive value of serum HER-2/neu extracellular domain (ECd) during trastuzumab-based therapy in patients with breast cancer. Proc AACR. 43:2002;490.
36. Bast R.C. Jr, Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer clinical practice guidelines of the American Society of Clinical Oncology . J Clin Oncol. 19:(6):2001;1865-1878.
37. Edgerton S.M., Merkel D.E., Moore D.H., Thor A.D. HER-2/neu/ErbB-2 status by immunohistochemistry and FISH clonality and progression with recurrence and metastases . Breast Cancer Res Treat. 64:(1):2000;55.
38. Braun S., Schlimok G., Heumos I., et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 61:(5):2001;1890-1895.